Activity
2K followers
-
John Neis shared thisThe Board of Directors of the National Venture Capital Association had another productive day in Washington DC yesterday. Following our Board meeting, we break into small groups and fan out between the Senate and Congressional office buildings to meet with members of Congress, their staff members, and committee staff members to discuss policy proposals that can have a big impact on our industry. I can't overstate the value of showing up. Given the high visibility of $1B+ funds and megadeals of over $100M in the press, it is not shocking that many often think that represents the most of the industry. Even those who know better are surprised to learn that the median sized fund is only $26M, that the average round is $20M, and in a place like Wisconsin where Venture Investors Health Fund has an office, the average round in the state is only $3M. Knowing that range in discussing topics from FDA reform to AI policy deepens their perspective on the impact of their legislation. I was making the rounds with Deena Shakir from Lux Capital and Navid Farzad of Frist Cressey Ventures, along with Ashlyn Roberts, our extraordinary healthcare lobbyist at the NVCA. Together we were a microcosm of the diversity of funds represented by the NVCA in size, backgrounds, focus, and geography. One can't help but be impressed by the deep domain knowledge developed by committee staffs and Congressional office staffs. They are deep thinkers about what makes a workable policy and are eager for feedback from venture capitalists and our portfolio companies. It is the first hand stories of portfolio companies that really resonate and makes it all real. It helps them understand how most of our companies live from one milestone driven financing to the next, and how burdensome, ambiguous, and unpredictable regulations can disproportionately impact small start-ups and harm our entrepreneurial ecosystem. For large well funded established companies, the delays and added costs are an inefficiency and annoyance. For early stage companies, it can be an existential threat, forcing them to idle or incur unexpected costs while the monthly cash burn continues, leaving them unable to achieve the targeted milestones with the cash they raised. The process required in DC is continuous. There are fresh faces on the Hill every two years and shifts in legislative priorities when there are changes in control. Thanks to Bobby Franklin for his leadership, to our lobbying team of Ashlyn Roberts, Caroline Moody Schellhas, and Diem-Mi L., and to my other my fellow Board members in other groups, Vineeta Agarwala, MD PhD, Gavin Christensen, Adam D'Augelli, Molly Bonakdarpour, Rick Yang, Ric Fenton, Ryan Nece, Stephen Socolof, Aziz Gilani, Graham Brooks, Nnamdi Okike, and Shauntel Garvey, for traveling to DC and taking the time to make the rounds on the Hill on behalf of all of us. If you are a VC an not a member, please join. We need your support and your voice to advance our mission.
-
John Neis posted thisAt Venture Investors Health Fund we are surrounded by brilliant people with answers to every conceivable question. However, we have learned that it requires care in the rush to provide answers because it may be more important to stop and think about whether we are asking the right questions. Last week the author George Saunders came to Madison on his latest book tour and was interviewed by my friend Amy Quan Barry, the poet / novelist / playwright / University of Wisconsin-Madison professor extraordinaire. She asked the degree to which his characters are fully conceived in advance, or whether their full identity is revealed during the writing process. They both agreed that they experienced discovery in the journey. Saunders referenced Einstein's quote "No worthy problem is ever solved within the plane of its original conception." Einstein believed that the capability to shift perspective was essential to finding the most meaningful answers. The perspective shift is often not easily achieved in a room of likeminded individuals. If given an hour to solve a problem, Einstein said he would spend 55 minutes asking questions to define the problem, and then five minutes on the solution. The best in art, science, and business share a similar trait. Too much certainty about your destination can cloud the sign posts on your path and lead you to the wrong place. We all bring valuable experience, knowledge, and perspective to the table. Perhaps more valuable and less intuitive is the ability to step outside that box and ask questions seen by inhabiting a different perspective. David Whyte wrote "The ability to ask beautiful questions, often in unbeautiful moments, is one of the great disciplines of life. And a beautiful question starts to shape your identity as much by asking it, as it does by having it answered. You just have to keep asking. And before you know it, you will find yourself actually shaping a different life, meeting different people, finding conversations that are leading you in those directions you wouldn't have seen before." Don't let a quick consensus of a group keep you from asking unanswered questions, even if you think everyone else in the room is more knowledgeable than you. And if the answer to a question seems obvious to you, view it as an opportunity to consider the perspective and perception that is causing it to be asked. The questions from those outside the bubble can prove to be more valuable than the immediate answers from those who presume to know.
-
John Neis posted thisAs a healthcare focused venture capitalist at Venture Investors Health Fund, I have met countless entrepreneurs who are passionate about improving human health and curing disease. Yesterday I spend the day listening to the pitches of a different group of entrepreneurs passionate about human and planet health at the conclusion of their week long strategic sprint with FARMpreneurs™. My wife chele isaac and I were invited to attend by an alumnus of the program who served as faculty, John Wepking, who together with his wife Halee own Meadowlark Organics, a family-owned organic farm and flour mill located in the Driftless area of Wisconsin. They specialize in growing and stone-milling culinary grains, corn, and beans using regenerative and sustainable practices. (If you bake, sign up for their grain shares.) They grow a small portion of their crops on a farm we own nearby, and we rotationally graze cattle for them in the summer. FARMpreneurs was started by Will Rosenzweig, a serial entrepreneur best known as founder of The Republic of Tea and co-founder of PHYSIC VENTURES LLC. He is now the Faculty Director, Sustainable Food Initiative, Center for Responsible Business Specialist in social entrepreneurship, food systems innovation and leadership at the University of California, Berkeley, Haas School of Business. The mission is to enhance the success, profitability, and resilience of community-based farming businesses through entrepreneurial business education programs, including their flagship week-long Strategic Sprint - an executive boot camp where farmers develop strategic plans, leadership skills, and collaborative networks to become changemakers in sustainable food systems. We all hear concerning stories about the exodus from rural farming towns, the aging of our faming workforce, and the depletion of our soil. It is exciting to see a growing younger generation that is attracted to the lifestyle, but also committed to advancing the availability of the highest quality hyperlocal food produced with sustainable practices that are beneficial to the soil and the environment. They too want to impact human health by connecting people with the food they eat, improving diets and avoiding disease in the first place. The lifestyle and businesses they are creating are deeply satisfying, but not easy. For those who have not inherited a family farm (most of them), the cost of entry is daunting. The range of knowledge and business and technical skills required for success is enormous. They deserve all the support they can get because they enrich our lives. You can help by being conscious about the food you eat. Eat what is in season. Eat what is produced locally. When possible, buy directly from the farmer. It will be fresher, more flavorful, and healthier for your well being and the future of our planet.
-
John Neis posted thisAmerican's views on the the regulation of AI do not follow strict partisan lines. The majority of voters in both parties oppose Federal preemption and want to allow States to regulate the industry. Perhaps the most significant factor in this view is based on mistrust of the Federal government. Three-quarters of voters trust their states more than the federal government to regulate the industry. At Venture Investors Health Fund we respect those concerns, but strongly believe that Federal preemption is the best national policy. Federal preemption is obviously not a new concept. For example, Federal preemption exists for the FDA, nuclear safety, and immigration. Imagine if that were not the case. The cost of developing drugs or medical devices would skyrocket if companies had to comply with 50 sets of laws for gaining approval and accessing the market. Our immigration debate would be even messier. AI advancement and international competitiveness would be similarly harmed without Federal preemption. The Constitution's Supremacy Clause provides that "the Laws of the United States shall be the supreme Law of the Land; and the Judges in every State shall be bound thereby, any Thing in the Constitution or Laws of any State to the Contrary notwithstanding." This language is the foundation for the doctrine of federal preemption, under which federal law supersedes conflicting state laws. However, the Supreme Court has ruled that the determination of whether federal law preempts state law relies on the primacy of Congressional intent. Absent an explicit (preferred) or implied intent of Congress, there is a presumption against preemption that leads to an interpretation that federal law should not be read to preempt laws involving the states powers. Donald Trump recently issued an executive order asserting Federal preemption over AI. Directionally, I agree with the policy, but I recognize it lacked the detail and specificity that most Americans are looking for regarding their safety concerns. The majority of the public will not be won over without bipartisan legislation that addresses their concerns, a bill that clearly delineates regulatory authority between the federal government (on things like safety and compliance) and states (like infrastructure construction and zoning). Further, the courts may not be won over without a law passed stating Congressional intent. The executive order is likely facing an argument against its authority based on the presumption against preemption. Congress needs to step up and do the right thing with a national policy that finds a balance that addresses the concerns of Americans while enabling this promising industry to flourish.
-
John Neis posted thisAt Venture Investors Health Fund, we believe that AI has extraordinary potential to have a positive impact on healthcare. In healthcare, we expect FDA oversight of AI, but many have called for a much broader regulatory framework for the technology. Last week President Trump issued an Executive Order (EO) titled “Ensuring A National Policy Framework For Artificial Intelligence”. It imposes Federal preemption over AI regulations. I had a mixed reaction. I strongly believe that the regulatory framework should be at the Federal level, but this EO may trigger litigation by those who believe that it is an overreach of presidential power. In these hyper partisan times, I also fear it will harden polarized views and may make it more difficult to to arrive at a policy consensus through the normal path of legislation. Two years ago, legislation seemed inevitable. Fears stoked by the popular press created a sense of urgency. Many regretted not acting early with social media and they weren't going to make that mistake again. But they couldn't reach consensus, so the states stepped in. That is not good. A patchwork quilt of regulation will undermine our international competitiveness and would be particularly burdensome for small innovative companies. It is the holiday season and AI is on my Christmas wish list I am sending to Congress instead of Santa: 1. The EO calls for more durable legislation Let it serve as a catalyst to do things the right way with bipartisan legislation. 2. In picking a size, remember that one size does not fit all. In medical devices, the FDA has three risk classes with differing requirements because a tongue depressor is not the same as an implantable cardiac pacemaker. AI will vary substantially in risk depending on the application and whether it relies on open source data or a closed proprietary data set. Do not impose the most stringent requirements on the most benign applications. 3. There is broad agreement about many of the concerns: the use of the tools to cause harm (reputationally or financially) through deception, defamation of public and private figures with deepfakes (while preserving freedom of speech through appropriately labeled satire), deception to create public harm or mass hysteria (the AI equivalent of shouting fire in a crowded theater), protections for children. Much of this is covered by existing law and give the governing agencies the power to adapt rules to AI capabilities. 4. Federal preemption for regulating the technology provides a consistent level playing field to enable us to compete internationally. Let the states regulate the infrastructure items that are normally under local control and have a local impact like zoning, power consumption, and water usage. 5. How about a stocking stuffer? We won't win the international race without remaining at the leading edge of research and having the most talented workforce. Put some money behind that.
-
John Neis posted thisOne of the most common ways to get a technology based business going is with a SBIR or STTR grant. That includes more than half the portfolio companies of Venture Investors Health Fund. Funding for these programs ran out on September 30, and it was not included in the continuing resolution to reopen the government. Congress needs to get this funded again ASAP. These grant programs are particularly important in the middle of the country where capital is not as abundant. It can considerably stretch funding from personal savings, friends and family, angels, and seed stage VC at the formative stages. The peer review process is reassuring to the earliest investors and the results of the funded work often provides the proof of principle that unleashes access to a broader group of investors. The success stories are seemingly endless. Beyond our portfolio, Amgen, Genzyme, Qualcomm and Illumina are among the industry giants that got their start with SBIR funding. The impact is beyond dispute. There is broad bipartisan support, but some in Congress are proposing changes to do things like capping the lifetime grants to those who fail to commercialize, targeting the mills who make it a primary business to attract grants. One thing contributing to the success of small companies is a sense of urgency. They are focused on priorities and want to get things done now. When caught in an unexpected funding or regulatory delay, they are disrupted and cash continues to burn on core monthly expenses. Once beyond the unexpected delay, the available cash is diminished, reducing the likelihood of achieving the value transforming milestones that open the doors to new investors and the next funding round. The programs are not broken but could be improved. However, allowing the program to lapse while potential changes are being debated can cause irreparable harm for the most fragile nascent companies. Congress needs to develop an entrepreneurial sense of urgency to help the current crop of early stage founders that they have left hanging and pass a continuing resolution while they contemplate changes.
-
John Neis shared thisVenture Investors Health Fund strongly endorses passage of the DEAL Act, the ICAN Act, and the HALOS Act, common sense reforms that that reduce unnecessary regulatory burdens and increases the flexibility for smaller funds and fund-of-funds. These reforms are particularly helpful to those of us in the middle of the country where the average fund is smaller. We want to remove obstacles for new fund formation in our region to foster more capital formation with emerging managers. These bills deserve bipartisan support. Special thanks to Bobby Franklin and his team at the National Venture Capital Association for their tireless effort to help legislators understand the practical implications of these bills with real world examples of the benefits. It is encouraging to see the passage in the House. Take the time to drop a quick note your Senators to indicate your support for passage in the Senate. Let's get these over the finish line.John Neis shared this🚨 Big week for capital markets legislation on Capitol Hill! The NVCA team has been pushing forward several bipartisan bills that will expand access to capital and strengthen opportunities for entrepreneurs and VC fund managers, especially emerging managers, all across the country: ✅ DEAL Act — Passed the House, Introduced in the Senate Modernizes the regulatory definition of a venture capital fund, giving VCs more flexibility to use secondaries and fund-of-funds strategies without triggering full SEC registration. ✅ ICAN Act — Passed the House Updates long-stagnant thresholds for “qualifying venture capital funds,” allowing modestly larger fund sizes and expanding participation for smaller accredited investors. ✅ HALOS Act — Introduced in the Senate Following House Passage Removes outdated regulatory barriers around Demo Days, enabling entrepreneurs and investors to connect earlier and more effectively.
-
John Neis shared thisAt Venture Investors Health Fund, we know the importance of a vibrant IPO market. Yesterday I joined National Venture Capital Association President Bobby Franklin and fellow Board members Shauntel Garvey and Aziz Gilani at the Nasdaq headquarters for a robust discussion with U.S. Securities and Exchange Commission Chairman Paul Atkins about his plans to make IPOs great again. There is reason for hope. Chairman Atkins has a clear understanding of the changes that have taken place in the public markets over the last 25 years that have interfered with the attractiveness of going public. He also demonstrated that he was really interested in our opinion about many of the proposals that are under consideration with a healthy exchange on the pros and cons. He made a compelling case for how a modernization of the regulations could actually improve investor protections while reducing the burden on small public companies. We promised to lean in and give feedback on any specific proposals to address these issues. The added benefit of meeting the SEC chairman at Nasdaq headquarters is that we had the fun of gathering with him at the podium to ring the closing bell!
-
John Neis shared thisWhen an entrepreneur says they have multiple shots on goal, are you hearing them say that they have an encore to follow their success, or that you might have to endure a failure before success is achieved? At Venture Investors Health Fund, we know it could be either, and in the latter case, the eventual success can far outweigh the cost of the early failure. However, it requires the courage of your convictions if you continue to believe after a disappointment. That isn't always an easy decision, The easy path is to walk away. Last week’s announcement that Otsuka Pharmaceutical Co., Ltd. had filed their NDA with the FDA for Centinafidine, an exciting new treatment for ADHD, is another indication that we are on the path to a huge success with our investment in Neurovance, which was acquired by Otsuka. My partner Paul Weiss learned about this opportunity from Frank Bymaster, a scientific advisor to another portfolio company. Together with Gary Tollefson and Phil Skolnick, these three were responsible for the development of several blockbuster CNS drugs while at Eli Lilly and Company, including Prozac, Cymbalta, and Zyprexa. They were drug development rock stars. Skolnick was at DOV Pharmaceuticals which had to discontinue a Phase 2 trial for a triple reuptake inhibitor anti-depressant before it was fully enrolled, and they put the asset up for sale. They broke the blind on the data they discovered statistically significant results despite not being fully enrolled. Paul Weiss contacted Campbell Murray, who was at Novartis Venture Fund at the time, and together we bought this and other assets for a mere $2M. We built a syndicate and funded a trial for Euthymics. Based on the data we had seen, we were extraordinarily confident of success. The plan was to find a buyer after a successful trial. As we considered that exit, we feared that little or no value would be placed on the other asset we had purchased, a different triple reuptake inhibitor for ADHD. So, we spun that asset into a separate company, Neurovance, and the same syndicate funded early trials. We were all stunned when Euthymics missed its clinical endpoint. In the meantime, Neurovance continued to progress. The most effective ADHD treatments today are stimulants with risk of abuse and diversion. Centinafidine was highly effective in its Phase 3 trials with low potential for abuse. Those combined attributes give it the blockbuster potential that attracted Otsuka and could make Neurovance one of the most successful investments in the history of our firm. Paul Weiss is a Canadian, so he knows how to play the rebound of a blocked puck and flick it into the corner of the net.John Neis shared thisIt’s very gratifying to see important progress continue for a program that has been close to our team for many years. Last week, Otsuka Pharmaceutical Co., Ltd. announced the submission of its New Drug Application (NDA) to the U.S. FDA for centanafadine, the first-in-class NDSRI candidate for patients living with ADHD. Centanafadine was originally developed at Neurovance, a Venture Investors Health Fund portfolio company that was acquired by Otsuka. The NDA spans data from four Phase 3 trials across children, adolescents, and adults, and represents a major milestone for everyone who has contributed to this work over the years. We’re pleased to see Otsuka advance this therapy into the regulatory review process, and we look forward to the potential outcome of patients gaining access to it. Here is the announcement from Otsuka: https://lnkd.in/ggPGxiwwOtsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults｜November 25, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults｜November 25, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.
John Neis commented on a post
1mo
It was great to work with you in the program Gaurav!
John Neis commented on a post
2mo
Scott,
Good questions. There has been a growing institutionalization of the VC industry in the last decade with a growing percentage of the total LP commitments going to very large funds and less to smaller funds. Most large funds are coastal. Our funds are mostly very small, smaller than the average single round of financing nationally of $30M. Our average financing round in Wisconsin is $3M. It is hard to build unicorns if we can’t competitively syndicate locally through the B round with follow on capacity beyond.
We have proven that it is possible to create big exits in the Midwest, and find serial entrepreneurs, but it took us 20 years to build the track record and achieve scale.
I’d challenge the assumption that we have made major public investments. We have dabbled. The scale needs to match the ambition.
John Neis replied to a comment
3mo
Chris Prestigiacomo set up a meeting at the time of this publication in September 2011 with Ken, Brian Birk of Sun Mountain, and me. We had a civil and spirited discussion followed by numerous e-mail exchanges in the week that followed about the merits of different models.
He was more interested in a program focused on small Wisconsin funds. That helps get seed and Series A funding to companies across the state.
I was an advocate for a model that could also include Wisconsin based offices from experienced coastal funds who made a firm commitment to invest here. Together with their coastal networks, it would make it far easier to build syndicate for national scale B and C rounds of $20M+. We saw it work in Michigan and Ohio.
We were both right. Wisconsin needs both. When we learned Walker would only support a $25M FoF, only his model made sense. He has done a great job with the resources available and he obtained improvements to the program when reauthorized.
-
John Neis liked thisJohn Neis liked thisCongratulations to Kevin Eliceiri, who will receive the inaugural Spencer Shorte Legacy Award at the ABRF - Association of Biomolecular Resource Facilities (ABRF) Annual Meeting today in Pittsburgh, PA. Kevin’s award will support the establishment of the Illuminating People Program, a platform for matching experienced and early-career researchers that recognizes the “bi-directional intellectual spark that good mentoring has on both the mentor and mentee.” Spencer Shorte was a deeply respected leader in the global bioimaging community, not only for his scientific gifts but also for his character. The award honors his legacy by recognizing someone who embodies these guiding core values, including “their dedication to uplifting their community, their quiet selflessness, their unwavering integrity, and the genuine warmth they bring to every interaction.” Morgridge is incredibly fortunate to have Kevin as an investigator of biomedical imaging and director of the Fab Lab at Morgridge — and an anchor of our imaging science community in Madison. BioImaging North America McPherson Eye Research Institute University of Wisconsin Department of Medical Physics Read more about the award ➡️ https://lnkd.in/gtyzDnF7
-
John Neis liked thisJohn Neis liked thisHistoSonics, Inc. announces today the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison #Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. “BPH affects millions of men worldwide and most of the existing treatment options require invasive procedures or lengthy recovery times,” said Mike Blue, Chairman and CEO, HistoSonics. “We believe histotripsy’s ability to mechanically destroy targeted tissue, completely non-invasively, has the potential to transform how BPH is treated. In addition, this milestone represents significant progress in our pursuit to expand the unique benefits of histotripsy over a significant number of serious clinical conditions throughout the body.” 🔗 Read our release: https://lnkd.in/g_eUthhF #HistoSonics #Histotripsy #MedTech #EdisonSystem #PatientsFirst
-
John Neis liked thisJohn Neis liked thisIncredible few days in Washington, D.C. spent fellow National Venture Capital Association board members for our spring board meeting and a day on Capitol Hill. I had the privilege of sitting down with Senator Catherine Cortez Masto and Representative Jimmy Panetta to talk about what's happening on the ground in venture — the founders building real companies, creating real jobs, and solving hard problems in healthcare, AI, and beyond. Both were genuinely engaged in understanding how smart policy can fuel the innovation ecosystem rather than slow it down. Overall, I have found these meetings over the last 4 years encouraging to me as a citizen and a voter, showing the intelligence, decency, and interest of lawmakers in our economy. After nearly two decades of backing seed-stage startups at Kickstart, I've seen firsthand how the right environment — the right capital, the right talent, and the right policy framework — can turn a great idea into a company that changes an industry. Also, it's important to remember that while there is incredible innovation on the coasts of the US, venture capital is equally important in all the States in between. Innovation, job- growth and blazing a path into the future for all of America. For example, the median size of a venture fund in the US is less than $30M and regulations tend to hurt these nascent ecosystems much more than the coasts. That's the story I wanted to bring to the Hill, and it's the story every policymaker should hear. Grateful for the National Venture Capital Association and the work they do to make sure our industry has a voice in these rooms. And grateful for the founders in our portfolio whose impact makes the case better than any talking points ever could. So great to be there with the NVCA team and my fellow board members. Bobby Franklin Ashlyn Roberts, Caroline Moody Schellhas, Diem-Mi L.-Mi L. Adam D'Augelli, Molly Bonakdarpour, Rick Yang, Ric Fenton, John Neis, Stephen Socolof, Aziz Gilani, Graham Brooks, Nnamdi Okike, and Shauntel Garvey #VentureCapital #NVCA #CapitolHill #Innovation #Startups #PublicPolicy
-
John Neis liked thisToday marks an important milestone as our team begins its next chapter as Abbott’s cancer diagnostics business. I’m honored to be part of this next phase and to help carry this work forward. I want to begin by recognizing Kevin Conroy. Kevin built more than a company. He built a mission-driven culture that has changed what’s possible in cancer screening and detection, and improved lives along the way. The work this team has done over the years has changed what’s possible in detection and care. Millions of patients and families have benefited because of the passion, persistence, and innovation that define this team. What we do is extraordinary because our teams are extraordinary. Now we have the opportunity to build on that foundation as part of Abbott. With Abbott’s global reach, scientific expertise, and operational scale, alongside the strengths this team has created, we can bring earlier detection and better answers to even more people around the world. Patients remain our North Star. Every decision we make should be something we would feel proud explaining to a patient who is counting on us. Grateful for the foundation and excited for what’s ahead.John Neis liked thisIt's official: Abbott and Exact Sciences have come together to transform how the world approaches cancer. We share a simple but powerful goal: helping people live fuller lives through better health. By bringing innovation and access to screening, we can detect cancer earlier and put more power into people's hands for personalized treatment decisions. https://abbo.tt/4uMMthY
-
John Neis liked thisJohn Neis liked thisVenture capital is best understood through the founders and ecosystem behind it. When I talk to policymakers, I make sure their stories — and their impact on America's future — take center stage. Today on Capitol Hill I shared what startups like Bluenote, Trial Library, Waymark , Mendaera, Inc. and Maven Clinic are doing at the intersection of healthcare and AI — and why the right policy environment makes that innovation possible. Proud to be an advocate for this ecosystem in my role as a board member for the National Venture Capital Association.
-
John Neis liked thisJohn Neis liked thisWelcome, NM Vintage Fund! As the Southwest venture ecosystem grows, NM Vintage Fund is focused on strengthening innovation across the region. Their investment in early-stage, high-growth companies reflects a clear commitment to advancing New Mexico’s economy and beyond. We’re excited to have them in our membership community and to support their work driving the state’s continued success.
-
John Neis liked thisJohn Neis liked thisThe average ratio of students to career services staff is about 2,000 to 1, according to the National Association of Colleges and Employers. Experts recommend 500 to 1. At the Morgridge Institute, that ratio is 150 to 1. It's a reflection of our dedication to training the next generation of scientists not just at the lab bench but beyond it. Meet Ellen Dobson, PhD, GCDF and Wesley D. Marner II, who lead our "whole scientist" approach to professional development 👉 https://lnkd.in/g49Mfn-N
-
John Neis liked thisJohn Neis liked thisGetting a smile from Kevin Conroy, CEO of Exact Sciences, when we saw each other at the Cologuard Classic by Exact Sciences Night of Champions was everything. I had the pleasure of sharing my cancer story at the first national sales meeting of Cologuard just before FDA approval was granted for the test in 2014. Kevin said tonight, “you were the first patient advocate I ever met. Look at what we’ve built together.” This year, there are nearly 500 colorectal cancer advocates attending various aspects of the tournament. I am incredibly proud to be representing MAN UP TO CANCER and also my work with Fight Colorectal Cancer. My dude, Ryan Vieth, is definitely here in spirit. I hope he is proud of what we’ve done together.
-
John Neis liked thisJohn Neis liked thisWay to go, Tom! Tom Dott was just re-elected to a three-year term on the United Way of Dane County Foundation Board of Trustees and is heading into his second year as Board Chair. Tom has long been a committed supporter of United Way of Dane County's mission, and through this volunteer effort, he’s helping to grow their endowment to expand their reach. Read more about Tom’s experience helping businesses and his community involvement on our website. https://ow.ly/4VHP30sUCHe
Experience & Education
-
Venture Investors
View John’s full experience
See their title, tenure and more.
or
Explore more posts
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named John Neis in United States
16 others named John Neis in United States are on LinkedIn
See others named John Neis